Depatuxizumab mafodotin  (Synonyms: ABT-414)

Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue^{[1][2][3][4][5]}.

Depatuxizumab mafodotin (up to 10 nM; up to 72 h) can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII^[2].
Depatuxizumab mafodotin (0-3.38 nM; 72 h) induces cell death in a dose-dependent manner in human head and neck squamous cell carcinoma (HNSCC) cell lines (UMSCC47 and FaDu) with high EGFR expression, with IC₅₀ values of 0.213 nM and 0.167 nM for UMSCC47 and FaDu cell lines, respectively^[3].
Depatuxizumab mafodotin exhibits significant cytotoxicity against tumor cell lines overexpressing wild-type or mutant forms of EGFR^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Depatuxizumab mafodotin (8 mg/kg; i.p.; every 4 days; 6 times in total) causes the loss of EGFRvIII expression in tumors in the orthotopic implantation model of LN-229 EGFRvIII cells in immunodeficient CD1 nude mice^[2].
Depatuxizumab mafodotin (4 mg/kg; i.p.; every 4 days; 4 times in total) significantly inhibits tumor growth in female nude mice xenografted with the FaDu cell line^[3].
Depatuxizumab mafodotin (1-10 mg/kg; once every 4 days; a total of 6 administrations) significantly delays tumor growth or inhibits tumor growth in mice bearing a variety of human tumor xenografts (such as A431, NCI-H1703, HCC827.ER.LMC, SCC-15), and can cause tumor regression and cure in some models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1585973-65-4

Liquid

Colorless to light yellow

[Depatuxizumab mafodotin]

Shipping with dry ice.

-80°C, protect from light

• [1]. Padovan M, et al. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers (Basel). 2021 Jun 3;13(11):2773.  [Content Brief]

  [2]. von Achenbach C, et al. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation. Mol Cancer Ther. 2020 Jun;19(6):1328-1339.  [Content Brief]

  [3]. Mani L, et al. Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer. Carcinogenesis. 2024 Jul 8;45(7):520-526.  [Content Brief]

  [4]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.  [Content Brief]

  [5]. Goss G D, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor[J]. Cancer, 2018, 124(10): 2174-2183.  [Content Brief]